HealthDay News - Mammogram's sensitivity lower in the initial five-year period after the first cancer
HealthDay News - Mammography screening for breast cancer may be less accurate among women with a personal history of breast cancer (PHBC), despite a higher underlying cancer rate, relative to women without PHBC, according to a study published in the Feb. 23 issue of the Journal of the American Medical Association.
Nehmat Houssami, MBBS, PhD, of the University of Sydney in Australia, and colleagues investigated the accuracy of mammography breast cancer screening among women with PHBC. They studied screening mammograms in women with and without a history of early-stage breast cancer and calculated the accuracy of the screening test (based on the scan's final assessment), the cancer detection rate, the interval cancer rate, and the stage at diagnosis.
The researchers found that, despite higher rates of cancer, cancer detection, and interval cancer, the mammogram's sensitivity was significantly lower among PHBC women compared to non-PHBC women (65.4 versus 76.5 percent). Screening sensitivity and detection was higher for in-situ tumors compared to invasive cancer in PHBC women. Among the PHBC women, the mammogram's sensitivity was lower in the initial five-year period after the first cancer, and subsequently increased. Most of the cancers detected in both groups of women were at the early stage.
"Screening mammography detects early-stage breast cancers in PHBC women but has lower accuracy relative to screening women without PHBC. Despite a relatively high interval cancer rate, interval cancers in PHBC women had generally favorable stage distributions," the authors write.
AbstractFull Text (subscription or payment may be required)
Copyright © 2011 HealthDay. All rights reserved.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.